Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | PGR | P06401 | 1/20 | 0.45 |
| ▸ | KAT6A | Q92794 | 3/20 | 0.44 |
| ▸ | CA2 | P00918 | 6/20 | 0.44 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MDM4 | O15151 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | TYR | P14679 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.44 |
| ▸ | CA5A | P35218 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30990675 | 0.85 | ALDH1A1 (0.43) | ALDH1A1TDP1HSD17B10PGRKAT6A | |
| SCHEMBL18600897 | 0.84 | TRPV4 (0.50) | ALDH1A1TDP1HSD17B10PGRCA2 | |
| SCHEMBL11300578 | 0.83 | SMN1; SMN2 (0.52) | ALDH1A1TDP1PGRKAT6ACA2 | |
| SCHEMBL28217372 | 0.83 | HDAC4 (0.50) | ALDH1A1TDP1PGRKAT6ACA2 | |
| SCHEMBL4193368 | 0.82 | ALDH1A1 (0.41) | ALDH1A1TDP1HSD17B10PGRKAT6A | |
| SCHEMBL4193371 | 0.82 | ALDH1A1 (0.41) | ALDH1A1TDP1HSD17B10PGRKAT6A | |
| SCHEMBL84445 | 0.82 | ALDH1A1 (0.47) | ALDH1A1TDP1PGRKAT6ACA2 | |
| SCHEMBL995303 | 0.80 | PTGS1 (0.53) | ALDH1A1TDP1HSD17B10KDM4ECYP3A4 | |
| SCHEMBL21471341 | 0.80 | KAT6A (0.44) | ALDH1A1TDP1PGRKAT6ACA2 | |
| SCHEMBL19631130 | 0.80 | ALDH1A1 (0.46) | ALDH1A1TDP1HSD17B10CA2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630529-B2 | GCN2 modulator compounds | Alesta Therapeutics BV (NL) | 2026-05-19 | — | — | US | disclosed |
| US-20230143059-A1 | GCN2 MODULATOR COMPOUNDS | Alesta Therapeutics BV (NL) | 2023-05-11 | — | — | US | disclosed |
| US-20230143059-A1 | GCN2 MODULATOR COMPOUNDS | Alesta Therapeutics BV (NL) | 2023-05-11 | — | — | US | disclosed |
| US-20230143059-A1 | GCN2 MODULATOR COMPOUNDS | Alesta Therapeutics BV (NL) | 2023-05-11 | — | — | US | disclosed |
| CN-115768750-A | GCN2 modulator compounds | 阿莱斯塔治疗公司 | 2023-03-07 | — | — | CN | disclosed |
| WO-2023274396-A1 | BENZAZEPINE HETEROCYCLIC COMPOUND AND APPLICATION THEREOF IN MEDICINE | 广东东阳光药业有限公司 | 2023-01-05 | — | — | WO | disclosed |
| CN-115557913-A | Benzoazaheterocyclic compounds and application thereof in medicines | 广东东阳光药业有限公司 | 2023-01-03 | — | — | CN | disclosed |
| WO-2021123237-A1 | 2-AMINO-N-(AMINO-OXO-ARYL-LAMBDA6-SULFANYLIDENE)ACETAMIDE COMPOUNDS AND THEIR THERAPEUTIC USE | Oxford Drug Design Limited (GB) | 2021-06-24 | — | — | WO | disclosed |
| WO-2017106607-A1 | POLYCYCLIC TLR7/8 ANTAGONISTS AND USE THEREOF IN THE TREATMENT OF IMMUNE DISORDERS | MERCK PATENT GMBH (DE) | 2017-06-22 | — | — | WO | disclosed |
| CN-105085450-A | Benzofuran derivatives, and preparation method and therapeutic action thereof | UNIV CHINA PHARMA | 2015-11-25 | — | — | CN | disclosed |
| US-20110178150-A1 | Use of Indole Derivatives as NURR-1 Activators for Treating Parkinson's Disease | LABORATORIES FOURNIER S.A. (FR) | 2011-07-21 | — | — | US | disclosed |
| US-7868030-B2 | FBPase inhibitors for diabetes | HOFFMANN-LA ROCHE INC. (US) | 2011-01-11 | — | — | US | disclosed |
| US-7728002-B2 | Use of pyrrolopyridine compounds for activating PPAR receptors and treatment of conditions involving such receptors | LABORATOIRES FOURNIER S.A. (FR) | 2010-06-01 | — | — | US | disclosed |
| US-20090239856-A1 | Use of Pyrrolopyridine Compounds for Activating PPAR Receptors and Treatment of Conditions Involving Such Receptors | LABORATOIRES FOURNIER S.A. (FR) | 2009-09-24 | — | — | US | disclosed |
| US-7557122-B2 | Pyrrolopyridine compounds, method of making them and uses thereof | LABORATOIRES FOURNIER S.A. (FR) | 2009-07-07 | — | — | US | disclosed |
| CN-101454301-A | Thiazole derivatives | HOFFMANN LA ROCHE (CH) | 2009-06-10 | — | — | CN | disclosed |
| EP-2032548-A1 | THIAZOLE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2009-03-11 | — | — | EP | disclosed |
| US-20080200495-A1 | Pyrrolopyridine Compounds, Method of Making Them and Uses Thereof | LABORATOIRES FOURNIER S.A. (FR) | 2008-08-21 | — | — | US | disclosed |
| WO-2007137962-A1 | THIAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-12-06 | — | — | WO | disclosed |
| US-20070281979-A1 | Fructose-1,6-bisphosphatase (FBPase) inhibitors, such as N-[(5-bromo-1,3-thiazol-2-yl)carbamoyl]3(difluoromethoxy)benzenesulfonamide, used as antidiabetic agents | HOFFMANN-LA ROCHE INC. | 2007-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12630529-B2 | GCN2 modulator compounds | NR3C1, GCN1, EIF2AK4 | ALDH1A1 4260/4885TDP1 3878/4885HSD17B10 733/4885 |
| US-20230143059-A1 | GCN2 MODULATOR COMPOUNDS | EIF2AK4, GPR119, GCN1 | ALDH1A1 4030/4885TDP1 3062/4885HSD17B10 512/4885 |
| US-20110178150-A1 | Use of Indole Derivatives as NURR-1 Activators for Treating Parkinson's Disease | NCOR1, NR0B1, NCOR2 | ALDH1A1 1383/4885TDP1 871/4885HSD17B10 2219/4885 |
| US-20090239856-A1 | Use of Pyrrolopyridine Compounds for Activating PPAR Receptors and Treatment of Conditions Involving Such Receptors | PPARD, PPARA, PPARG | ALDH1A1 1314/4885TDP1 2449/4885HSD17B10 1620/4885 |
| US-20080200495-A1 | Pyrrolopyridine Compounds, Method of Making Them and Uses Thereof | LIPG, PCSK9, PNLIP | ALDH1A1 1350/4885TDP1 26/4885HSD17B10 581/4885 |
| US-20070281979-A1 | Fructose-1,6-bisphosphatase (FBPase) inhibitors, such as N-[(5-bromo-1,3-thiazol-2-yl)carbamoyl]3(difluoromethoxy)benzenesulfonamide, used as antidiabetic agents | FBP1, PFKFB1, PFKFB3 | ALDH1A1 565/4885TDP1 3045/4885HSD17B10 1696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.